Clinical & Economic outcomes from RPM (Remote Patient Monitoring)

What are the thresholds of evidence, both clinical and economic, required by digital products operating in the RPM space?  Do these thresholds vary by region/ jurisdiction, by clinical/ therapy area of operation, by stakeholder (hospital, payer, pharma, etc)? A survey from 2020 suggested that 55 to 58% of the European physicians believe that Remote Patient Monitoring (RPM) will play a key role in the future of care. But in order to successfully gain adoption, we need to understand the above. Join to have an informal conversation with other thought leaders on: